Daewoong's Bersiporocin Receives 'Orphan Drug Designation' in Europe
SEOUL, South Korea, Feb. 6, 2023 /PRNewswire/ -- The world's first-in-class candidate substance against idiopathic pulmonary fibrosis, 'Bersiposocin' (DWN12088), which is under development Daewoong Pharmaceutical, has entered its Phase II clinical administration.